<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468219</url>
  </required_header>
  <id_info>
    <org_study_id>IR00002509/FWA</org_study_id>
    <nct_id>NCT02468219</nct_id>
  </id_info>
  <brief_title>Cardiovascular Rehabilitation in Patients With Severe Aortic Stenosis Submitted to Valvar Correction</brief_title>
  <acronym>CARE-AS-MOTION</acronym>
  <official_title>Cardiovascular RehAbilitation in Patients With Severe AoRtic StEnosis Submitted to Valvar Correction: Effects on Muscle Architecture, Tissue Oxygenation, EndoThelial Function, Inflammatory Profile, and AutoNomic Control - Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Health Science of Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Irmandade Santa Casa de Misericórdia de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be evaluate the autonomic, endothelial and hemodynamic functions, inspiratory
      muscle strength, peripheral tissue oxygenation, peripheral and respiratory muscle
      architecture, and inflammatory profile of severe AS patients submitted undergoing to valve
      replacement (sAVR) or transcatheter aortic valve implantation (TAVI), and their influence on
      the pathophysiological mechanisms involved in cardiovascular rehabilitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Aortic stenosis (AS) is a disease characterized by the inadequate valve opening,
      compromising the cardiac output. Surgical aortic valve replacement (sAVR) is the procedure
      indicates for valve repair in AS symptomatic cases whereas the transcatheter aortic valve
      implantation (TAVI) is the procedure indicates for sAVR contraindicated cases.

      Objective: To evaluate the effect of the cardiac rehabilitation program (pre-procedure, early
      post-procedure, and late post-procedure) in autonomic, endothelial and hemodynamic functions,
      inspiratory muscle strength, peripheral tissue oxygenation, peripheral and respiratory muscle
      architecture, and inflammatory profile of severe AS patients submitted to a valve repair
      procedure (sAVR or TAVI).

      Methods: The present study will be a randomized double-blind clinical trial in patients
      indicated to valve repair procedure. This research will be divided into four phases: phase 1
      (pre-procedure); phase 2 (early post-procedure); phase 3 (late post-procedure) and phase 4
      (follow-up). Phase 1: participants will be randomized in PR-I (pre-intervention) or PR-C
      (control). Pre-procedure rehabilitation program will consist of daily neuromuscular
      electrical stimulation (NMES) in knee extensor muscles and inspiratory muscle training (IMT)
      sessions. PR-C group will receive daily visits, but with a NMES + IMT protocols using a
      minimal load. Phase 2: a new random will be done between ER-II or ER-CI (intervention) and
      ER-IC or ER-CC (control). Intervention groups will undertake an early post-procedure
      rehabilitation (NMES in knee extensor muscle plus IMT for six weeks). Control groups will
      receive the same protocol using a minimal load without load progression. Phase 3: all
      patients will be referred to the conventional cardiac rehabilitation program (aerobic and
      resistance training) for 8-weeks. Phase 4: follow-up (no interventions), will be done after
      3, 6, 9 and 12 months. Assessment protocol will be composed by cardiopulmonary exercise test,
      autonomic (heart rate variability), endothelial (flow-mediated vasodilation), hemodynamic
      function (cardiothoracic impedance) functional capacity (six-minute walk test), maximum
      inspiratory pressure, peripheral and respiratory muscle architecture (ultrasonography), and
      tissue oxygenation (near-infrared spectroscopy), and inflammatory profile (OxLDL, TGF-β,
      TNF-α, IL-1b, IL-10 and ICAM-1) Appropriate statistic tests will be used to compare the
      time-rehabilitation (experimental vs sham) and group-interaction (sAVR vs TAVI). If samples
      are abandoned or lost, basal data will be double entered to characterize the
      intention-to-treat analysis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will be divided into four phases: phase 1 (pre-procedure rehabilitation); phase 2 (early post-procedure rehabilitation); phase 3 (late post-procedure rehabilitation), and phase 4 (follow-up).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiorespiratory function</measure>
    <time_frame>Changes from 8 and 16 weeks</time_frame>
    <description>Peak oxygen consumption (VO2PEAK), among other physiologic markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autonomic function</measure>
    <time_frame>Change from 2, 8 and 16 weeks</time_frame>
    <description>will be evaluated by heart rate variability using a wrist heart rate monitor following the recommendations of ESC/NASPE Task Force.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Changes from 2, 8 and 16 weeks</time_frame>
    <description>will be investigated by endothelium-dependent flow-mediated vasodilation (FMD) technique following the International Brachial Artery Reactivity Task Force.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic function</measure>
    <time_frame>Changes from 2, 8 and 16 weeks</time_frame>
    <description>will be evaluated the cardiac output using a cardiothoracic impedance device (noninvasive approach).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory profile</measure>
    <time_frame>Changes from 2, 8 and 16 weeks</time_frame>
    <description>Plasma levels will be determined by enzyme-linked immunosorbent assay using commercial systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory muscle strength</measure>
    <time_frame>Changes from 2, 8 and 16 weeks</time_frame>
    <description>Will be assessed as maximum inspiratory pressure (MIP) using a digital device following recommendations of the American Thoracic Society and European Respiratory Society.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle architecture (peripheral muscles)</measure>
    <time_frame>Changes from 8 and 16 weeks</time_frame>
    <description>Will be evaluated the muscle thickness (cross-sectional area) of quadriceps using a ultrasonography system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle architecture (respiratory muscles)</measure>
    <time_frame>Changes from 8 and 16 weeks</time_frame>
    <description>Will be evaluated the diaphragm thickness (cross-sectional area) of quadriceps using a ultrasonography system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue oxygenation</measure>
    <time_frame>Changes from 2, 8 and 16 weeks</time_frame>
    <description>near-infrared spectroscopy (NIRS) will be used to verify muscle oxygenation (quadriceps and respiratory muscles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity</measure>
    <time_frame>Changes from 8 and 16 weeks</time_frame>
    <description>The patients under favorable clinical conditions will be functionally evaluated by the Six-Minute Walk Test (6MWT) according to current guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Change from 3, 6 and 12 months post protocol</time_frame>
    <description>to evaluate the survival rate of the patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>aortic valve replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with aortic stenosis submitted to aortic valve replacement procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>transcatheter aortic valve implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with aortic stenosis who underwent to transcatheter aortic valve implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>cardiovascular rehabilitation program</intervention_name>
    <description>Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).
Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).
Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training.</description>
    <arm_group_label>aortic valve replacement</arm_group_label>
    <arm_group_label>transcatheter aortic valve implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patients NYHA class II-IV who has not participated in a CRP three
        months before recruitment; older than 40 years; of both genders; with degenerative AS and
        indication for valve repair. The patients will not know which protocol to undergo.

        Exclusion Criteria: patients with low cognitive level to perform the assessment or
        intervention procedures; that exhibit unstable angina or any contraindications for the
        treatment or measurements; as well musculoskeletal, cerebrovascular, or psychiatric disease
        that prevents their participation in the research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlus Karsten, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Health Science of Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlus Karsten, PhD</last_name>
    <phone>55 51 33038876</phone>
    <email>mkarsten@ufcspa.edu.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Marlus Karsten</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90050-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Marlus Karsten, PhD</last_name>
      <phone>+55 51 33038876</phone>
      <email>mkarsten@ufcspa.edu.br</email>
    </contact>
    <contact_backup>
      <last_name>Gustavo S Ribeiro</last_name>
      <phone>+55 51 99848530</phone>
      <email>gustavosr@ufcspa.edu.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Montemezzo D, Fregonezi GA, Pereira DA, Britto RR, Reid WD. Influence of inspiratory muscle weakness on inspiratory muscle training responses in chronic heart failure patients: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2014 Jul;95(7):1398-407. doi: 10.1016/j.apmr.2014.02.022. Epub 2014 Mar 13. Review.</citation>
    <PMID>24631801</PMID>
  </reference>
  <reference>
    <citation>Russo N, Compostella L, Tarantini G, Setzu T, Napodano M, Bottio T, D'Onofrio A, Isabella G, Gerosa G, Iliceto S, Bellotto F. Cardiac rehabilitation after transcatheter versus surgical prosthetic valve implantation for aortic stenosis in the elderly. Eur J Prev Cardiol. 2014 Nov;21(11):1341-8. doi: 10.1177/2047487313494029. Epub 2013 Jun 11.</citation>
    <PMID>23757283</PMID>
  </reference>
  <reference>
    <citation>Völler H, Salzwedel A, Nitardy A, Buhlert H, Treszl A, Wegscheider K. Effect of cardiac rehabilitation on functional and emotional status in patients after transcatheter aortic-valve implantation. Eur J Prev Cardiol. 2015 May;22(5):568-74. doi: 10.1177/2047487314526072. Epub 2014 Feb 27.</citation>
    <PMID>24577878</PMID>
  </reference>
  <reference>
    <citation>Fauchère I, Weber D, Maier W, Altwegg L, Lüscher TF, Grünenfelder J, Nowak A, Tüller D, Genoni M, Falk V, Hermann M. Rehabilitation after TAVI compared to surgical aortic valve replacement. Int J Cardiol. 2014 May 15;173(3):564-6. doi: 10.1016/j.ijcard.2014.03.121. Epub 2014 Mar 21.</citation>
    <PMID>24713461</PMID>
  </reference>
  <reference>
    <citation>Sbruzzi G, Ribeiro RA, Schaan BD, Signori LU, Silva AM, Irigoyen MC, Plentz RD. Functional electrical stimulation in the treatment of patients with chronic heart failure: a meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil. 2010 Jun;17(3):254-60. Review.</citation>
    <PMID>20560163</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Health Science of Porto Alegre</investigator_affiliation>
    <investigator_full_name>Marlus Karsten</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>transcatheter aortic valve implantation</keyword>
  <keyword>frailty</keyword>
  <keyword>cardiac rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

